Johnson & Johnson (NYSE:JNJ) and Pfizer (NYSE:PFE) rank as the biggest of big pharma companies in the United States. Both companies trace their roots back to the 19th century. Both generate enormous amounts of cash flow and pay solid dividends.
Over the past 12 months, Pfizer has been the clear winner between these two blue-chip pharma stocks. But which is the better pick for investors now? Here's how J&J and Pfizer compare.
Image source: Getty Images.
The case for Johnson & JohnsonJohnson & Johnson's solid Q2 performance highlights several reasons to like the stock. First, the company is diversified into several areas of healthcare. J&J isn't just a big pharma company. It also ranks as a leader in consumer healthcare and medical devices. These two segments combined generate more revenue for J&J than its pharmaceuticals business does.�
Another thing Johnson & Johnson's second-quarter results show is the company's ability to make acquisitions that move the needle. For example, last year's acquisition of Swiss drugmaker Actelion contributed an additional $665 million in revenue in Q2 that J&J wouldn't have had otherwise.
But Johnson & Johnson also claims several blockbuster drugs that continue to enjoy strong momentum. Immunology drugs Stelara and Simponi are big winners for the company and are more than offsetting�declines for Remicade, which faces competition from biosimilars. J&J's Invega neuroscience franchise is also performing well.�The company is exceptionally strong in oncology, with soaring sales for Darzalex, Imbruvica, and Zytiga.�
What about Johnson & Johnson's pipeline? The company claims more than 40 late-stage programs. J&J awaits European approval of Erleada, a promising prostate cancer drug that won FDA approval earlier this year. It expects to submit several more oncology drugs for approval over the next three years, including niraparib�for treating prostate cancer and CAR-T therapy JNJ-4528 for treating multiple myeloma.
J&J's dividend is another big plus for the stock. Its yield currently stands at 2.86%. The company has increased its quarterly dividend for 56 consecutive years.
The case for PfizerPfizer isn't as diversified as J&J and could become even less so as it contemplates the possibility of spinning off its consumer health business. However, there's a lot to like about Pfizer's core pharmaceuticals business.
The drugmaker claims three tremendously successful drugs that should continue to generate growth well into the future. Market research firm EvaluatePharma thinks that Eliquis, which Pfizer co-markets with Bristol-Myers Squibb, will be the No. 5 best-selling drug in the world within a few years. Breast cancer drug Ibrance and immunology drug Xeljanz also enjoy strong sales momentum.
We could soon add more drugs to this list. Pfizer and partner Merck�won FDA approval for Steglatro, Steglujan, and Segluromet in treating type 2 diabetes in December 2017. These drugs could together be another blockbuster franchise for Pfizer.
Pfizer's pipeline also includes over 30 programs in late-stage development or awaiting approval. Three oncology drugs that look especially promising are�dacomitinib, lorlatinib, and talazoparib. Pfizer also hopes to step up its rare-disease game, with tafamidis meglumine awaiting FDA approval as a treatment for transthyretin familial amyloid polyneuropathy and sickle cell disease candidate rivipansel in phase 3 testing.�
You won't find many big pharma dividends better than Pfizer's. Its dividend currently yields 3.66%. Over the past five years, Pfizer has increased its dividend by nearly 42% -- higher than J&J's dividend increases of 36% during the period.
Better buyBoth Johnson & Johnson and Pfizer face some challenges. Without its acquisitions and help from currency fluctuations, J&J's revenue growth has been modest. Pfizer continues to be held back by declining sales for drugs that have lost exclusivity and continued product shortages with its sterile injectables business.
However, I like both of these stocks despite the headwinds they face. Over the long run, my view is that both J&J and Pfizer will deliver solid total returns to investors.
Which is the better pick right now? I think the nod goes to Pfizer -- mainly because of the company's higher dividend yield. My hunch is that both companies will generate earnings growth at similar levels over the next few years. But Pfizer's better dividend should allow the stock to produce greater total returns than J&J will.
It's a close call, though. I don't think long-term investors can go wrong with buying either of these stocks.
Shares of Diplomat Pharmacy Inc (NYSE:DPLO) dropped 10.4% during mid-day trading on Friday . The company traded as low as $22.21 and last traded at $22.33. Approximately 3,371,300 shares traded hands during mid-day trading, an increase of 267% from the average daily volume of 918,233 shares. The stock had previously closed at $24.93.
Small and underpowered in its day, the Subaru 360 feels even more out of place on modern roads. 
Even by the standards of cheap cars, the Subaru 360 was spartan. 
ValuEngine lowered shares of Flotek Industries (NYSE:FTK) from a hold rating to a sell rating in a research report sent to investors on Monday morning.
Wall Street brokerages predict that Axalta Coating Systems Ltd (NYSE:AXTA) will post earnings of $0.36 per share for the current fiscal quarter, according to Zacks Investment Research. Four analysts have provided estimates for Axalta Coating Systems’ earnings, with the highest EPS estimate coming in at $0.39 and the lowest estimate coming in at $0.31. Axalta Coating Systems posted earnings of $0.31 per share during the same quarter last year, which would suggest a positive year over year growth rate of 16.1%. The firm is scheduled to issue its next earnings results on Thursday, August 2nd.
News coverage about Finisar (NASDAQ:FNSR) has been trending somewhat positive on Tuesday, Accern Sentiment Analysis reports. Accern identifies positive and negative press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Finisar earned a media sentiment score of 0.09 on Accern’s scale. Accern also assigned media stories about the technology company an impact score of 48.3712393394037 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days. 
Shares of AngloGold Ashanti Limited (NYSE:AU) hit a new 52-week low during trading on Friday . The company traded as low as $7.90 and last traded at $8.15, with a volume of 45855965 shares. The stock had previously closed at $8.68.